文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

SAFE研究:沙格雷酯在股腘动脉介入治疗中疗效的随机对照试验研究方案

SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-09-22

本研究为开放标签、多中心、前瞻性随机对照试验,比较阿司匹林联合缓释沙格雷酯与阿司匹林联合氯吡格雷在股腘动脉外周动脉疾病患者血管内治疗后预防再狭窄的效果。主要结局为6个月随访期内CT血管造影或导管血管造影定义的管腔缩减>50%的再狭窄率,旨在显示缓释沙格雷酯相较于氯吡格雷在再狭窄率方面的非劣效性。

要点

  • 研究纳入因新发股腘动脉病变狭窄或闭塞需血管内治疗的患者。
  • 试验组口服阿司匹林100 mg联合缓释沙格雷酯300 mg,对照组口服阿司匹林100 mg联合氯吡格雷75 mg,每日一次,共6个月。
  • 主要结局为6个月随访期内CT血管造影或导管血管造影定义的管腔缩减>50%的再狭窄率。

核心结论

  • 本研究旨在显示缓释沙格雷酯相较于氯吡格雷在股腘动脉病变患者血管内治疗后6个月再狭窄率方面的非劣效性。

研究设计与样本

  • 本研究为开放标签、多中心、前瞻性随机对照临床试验。
  • 纳入标准为因新发股腘动脉病变狭窄或闭塞需血管内治疗的患者。
  • 试验组接受阿司匹林100 mg联合缓释沙格雷酯300 mg(Anplone®)口服,每日一次,共6个月。
  • 对照组接受阿司匹林100 mg联合氯吡格雷75 mg口服,每日一次,共6个月。

主要发现

  • 主要结局为6个月随访期内CT血管造影或导管血管造影定义的管腔缩减>50%的再狭窄率。
  • 次要结局包括6个月内发生的靶病变血运重建、大出血、同侧大截肢、全因死亡及所有不良事件。

关键数值与推荐

  • 再狭窄定义为6个月随访期内CT血管造影或导管血管造影显示管腔缩减>50%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarpogrelate is expected to reduce restenosis by protecting blood vessels from oxidative stress and vascular endothelial dysfunction as well as by acting as an antiplatelet agent after endovascular treatment (EVT). This trial was designed to compare aspirin plus sustained-release (SR) sarpogrelate with aspirin plus clopidogrel for the prevention of restenosis in patients with femoro-popliteal (FP) peripheral artery disease (PAD) who underwent EVT. METHODS/DESIGN: This is an open label, multicenter, prospective randomized controlled clinical trial. Patients will be eligible for inclusion in this study if they require EVT for stenosis or occlusion of a de novo FP lesion. Patients in each group will receive aspirin 100 mg with clopidogrel 75 mg or aspirin 100 mg with SR sarpogrelate 300 mg (Anplone®) orally once a day for six months. The primary outcome of the study is the restenosis rate, defined as > 50% luminal reduction by computed tomography angiography or catheter angiography in the six-month follow-up period. Secondary outcomes include target lesion revascularization, major bleeding, ipsilateral major amputation, all-cause mortality, and all adverse events that take place in those six months. DISCUSSION: This study is a multicenter randomized controlled trial designed to show non-inferiority in terms of the re-stenosis rate of SR sarpogrelate compared to clopidogrel for EVT for PAD in FP lesion patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02959606 . Registered on 9 November 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ahn S, Lee J, Min SK, et al. SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28938905. doi:10.1186/s13063-017-2155-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。